In summary, this study demonstrates that adjunctive evolocumab therapy significantly improves clinical outcomes and inhibits the elevation of the plasma IL-6 levels compared with atorvastatin monotherapy in AIS patients, with no significant changes in peripheral blood T lymphocyte subsets. Here, IL6 is linked to androgen insensitivity syndrome.